PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Classificação em ações #1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Preço da ação
$36.89
Valor de mercado
$15.25B
Variação (1 dia)
-1.28%
Variação (1 ano)
144.12%
País
TW
Negociar PharmaEssentia Corporation (6446)

Categoria

Healthcare
Rácio P/B de PharmaEssentia Corporation (6446)
Rácio P/B em October 2026 TTM: 13.50
De acordo com os relatórios financeiros mais recentes e o preço das ações da PharmaEssentia Corporation, o rácio P/B atual (TTM) é 13.50. No final de 2023, o rácio P/B era 4.70.
Histórico do rácio P/B da PharmaEssentia Corporation de 2010 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
2026 (TTM) 13.50 85.23%
2024 7.29 54.92%
2023 4.70 -57.85%
2022 11.16 -36.95%
2021 17.70 205.50%
2020 5.79 -44.22%
2019 10.39 -30.22%
2018 14.88 65.96%
2017 8.97 16.17%
2016 7.72 -85.09%
2015 51.79 198.70%
2014 17.34 0.82%
2013 17.20 -64.44%
2012 48.36 -92.11%
2011 613.14 490.71%
2010 103.80 0.00%
Rácio P/B de empresas semelhantes ou concorrentes